ArticleCardiovascular diabetology2018
Bone markers and cardiovascular risk in type 2 diabetes patients.
Article in Cardiovascular diabetology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it, 29 citations in OpenAlex.
- Association of vitamin K with cardiovascular events and all-cause mortality: a systematic review and meta-analysis.European journal of nutrition · 2019Pooled it
- Serum alkaline phosphatase levels and the risk of new-onset diabetes in hypertensive adults.Cardiovascular diabetology · 2020Trial
- Carboxylated Osteocalcin as an Independent Predictor of Mean Arterial Pressure and the Atherogenic Index in Adults.International journal of molecular sciences · 2025Article
- Plasma Olink Proteomics Reveals Novel Biomarkers for Prediction and Diagnosis in Dilated Cardiomyopathy with Heart Failure.Journal of proteome research · 2024Article
- Immunoregulatory Roles of Osteopontin in Diseases.Nutrients · 2024Review
- Long-term risks of cardiovascular-specific mortality among myeloproliferative neoplasms patients.Therapeutic advances in hematology · 2024Article
- Beyond the Cardiovascular Effects of Glucagon-like Peptide-1 Receptor Agonists: Body Slimming and Plaque Stabilization. Are New Statins Born?Biomolecules · 2023Review
- Association of bone turnover biomarkers with severe intracranial and extracranial artery stenosis in type 2 diabetes mellitus patients.World journal of diabetes · 2023Article
- Association of Bone Turnover Markers with Type 2 Diabetes Mellitus and Microvascular Complications: A Matched Case-Control Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2023Article
- Sclerostin aggravates cardiac remodeling after myocardial infarction by inhibition of Wnt/β-catenin signaling pathway.Journal of thoracic disease · 2022Article
- Plasmatic osteopontin and vascular access dysfunction in hemodialysis patients: a cross-sectional, case-control study (The OSMOSIS Study).Journal of nephrology · 2022Article
- Relationships of Serum Bone Turnover Markers With Metabolic Syndrome Components and Carotid Atherosclerosis in Patients With Type 2 Diabetes Mellitus.Frontiers in cardiovascular medicine · 2022Article
- Association of bone biomarkers with advanced atherosclerotic disease in people with overweight/obesity.Endocrine · 2021Article
- Patients with type 2 diabetes present with multiple anomalies of the pancreatic arterial tree on abdominal computed tomography: comparison between patients with type 2 diabetes and a matched control group.Cardiovascular diabetology · 2020Article
- Impaired bone matrix glycoprotein pattern is associated with increased cardio-metabolic risk profile in patients with type 2 diabetes mellitus.Journal of endocrinological investigation · 2019Article
- The Discovery and Development of Liraglutide and Semaglutide.Frontiers in endocrinology · 2019 · on this mapReview
- The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoEJACC. Basic to translational science · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
Abstract
backgroundVascular calcifications are associated with a three- to fourfold increased risk of cardiovascular disease (CVD) and are highly prevalent in type 2 diabetes patients. Emerging evidence indicates that vascular calcification is a process of active bone formation regulated by stimulators and inhibitors of calcification. Therefore, this study aimed to evaluate whether six bone markers are associated with CVD risk in patients with type 2 diabetes.
methodsWe used data of a case-cohort study, nested in the EPIC-NL cohort, comprising 134 CVD cases and a random subcohort of 218 participants, all with type 2 diabetes at baseline. Six bone markers (osteocalcin, osteopontin, osteonectin, osteoprotegerin, alkaline phosphatase and sclerostin) were measured in baseline plasma samples with multiplex assays and information on CVD events was obtained. The association of bone makers with CVD risk was evaluated using Cox proportional hazard analyses.
resultsHigher concentrations of plasma osteopontin were associated (p
conclusionsHigher osteopontin concentrations were associated with an increased CVD risk in type 2 diabetes patients. No consistent associations were found for the other five bone markers and risk of CVD in type 2 diabetes patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.